Actively Recruiting
Study of INT230-6 Injection Before Neoadjuvant Immuno-chemotherapy in Early Triple-negative Breast Cancer Patients to Improve Tumor Response
Led by Swiss Cancer Institute · Updated on 2026-10-23
61
Participants Needed
10
Research Sites
165 weeks
Total Duration
AI-Summary
What This Trial Is About
Triple-negative breast cancer TNBC is a particularly aggressive form of breast cancer with higher relapse and mortality rates compared to other types. Achieving a pathological complete response pCR in the tumor and affected lymph nodes is an important factor for better outcomes. This phase 2 trial evaluates whether the drug INT230-6 administered before surgery can increase the pCR rate in early TNBC patients and examines its tolerability and other outcomes such as breast-conserving surgery possibilities. Participants are randomized into two groups one receives a single injection of INT230-6 directly into the primary tumor followed by standard neoadjuvant immuno-chemotherapy and surgery, while the other receives no initial injection but starts the same immuno-chemotherapy and surgery regimen. The neoadjuvant therapy follows the Keynote-522 protocol including pembrolizumab combined with chemotherapy drugs given over approximately 24 weeks, followed by surgery and further assessments. During the study, participants undergo tumor assessments by MRI and pathological evaluation after surgery to measure the pCR in breast and lymph nodes. Researchers monitor safety, treatment response, event-free survival, and breast conservation rates, with evaluations occurring up to about 30 weeks post-treatment start. The trial is conducted under the oversight of the Swiss Cancer Institute and includes regular clinical visits, imaging, laboratory tests, and questionnaires to assess outcomes and tolerability over the study period.
CONDITIONS
Brief Title
Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK
Research Team
J
Jana Musilova, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here